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Abstract
Background: Colon capsule endoscopy (CCE) and CT colonography (CTC) are minimally invasive techniques for
colorectal cancer (CRC) screening. Our objective is to compare CCE and CTC for the identification of patients with
colorectal neoplasia among participants in a CRC screening programme with positive faecal immunochemical test (FIT).
Primary outcome was to compare the performance of CCE and CTC in detecting patients with neoplastic lesions.
Methods: The VICOCA study is a prospective, single-centre, randomised trial conducted from March 2014 to May 2016;
662 individuals were invited and 349 were randomised to CCE or CTC before colonoscopy. Endoscopists were blinded
to the results of CCE and CTC.
Results: Three hundred forty-nine individuals were included: 173 in the CCE group and 176 in the CTC group. Two
hundred ninety individuals agreed to participate: 147 in the CCE group and 143 in the CTC group. In the intention-to-
screen analysis, sensitivity, specificity and positive and negative predictive values for the identification of individuals
with colorectal neoplasia were 98.1%, 76.6%, 93.7% and 92.0% in the CCE group and 64.9%, 95.7%, 96.8% and 57.7% in
the CTC group. In terms of detecting significant neoplastic lesions, the sensitivity of CCE and CTC was 96.1% and 79.3%,
respectively. Detection rate for advanced colorectal neoplasm was higher in the CCE group than in the CTC group
(100% and 93.1%, respectively; RR = 1.07; p = 0.08). Both CCE and CTC identified all patients with cancer. CCE detected
more patients with any lesion than CTC (98.6% and 81.0%, respectively; RR = 1.22; p = 0.002).
Conclusion: Although both techniques seem to be similar in detecting patients with advanced colorectal neoplasms,
CCE is more sensitive for the detection of any neoplastic lesion.
Trial registration: ClinicalTrials.gov Identifier: NCT02081742. Registered: September 16, 2013.
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 Colorectal cancer (CRC) is the fourth leading cause
of cancer death worldwide and the second in
Europe. The introduction of minimally invasive
methods for colorectal cancer diagnosis is
recommended in order to increase patient’s
adherence.
 Colon capsule endoscopy and CT colonography are
two minimally invasive techniques with high
sensitivity and specificity in detecting colorectal
cancer. No comparative and prospective studies
have been done between both tests so far.
What is new here?
 Colon capsule endoscopy detected more patients
with any neoplastic lesion (regardless of size).
 Colon capsule endoscopy is superior to CT
colonography for detecting patients with significant
lesions (i.e. ≥ 6 mm in size at colonoscopy), with a
slightly lower specificity.
 Colon capsule endoscopy and CTC are well-
accepted, useful and safe strategies, with similar
performance in terms of advanced neoplasm
detection rate. However, CCE may benefit from a
higher sensitivity for detecting small, flat, sessile
and serrated lesions. The impact of these results
in terms of overall effectiveness deserves further
investigation.
Colorectal cancer (CRC) is the fourth leading cause of
cancer death worldwide and the second in Europe. Over
the last decade, mortality has decreased due to the intro-
duction of new treatments and screening programmes [1,
2]. Indeed, clinical guidelines recommend screening in
average-risk (individuals over the age of 50 who have no
additional risk factors) and high-risk (i.e. hereditary CRC
syndromes, individuals with first-degree relatives with CRC,
or patients with inflammatory bowel disease) populations.
There are different strategies for CRC screening, but the
most extensively accepted are colonoscopy, flexible
sigmoidoscopy and faecal occult blood testing (i.e. faecal
immunochemical tests [FIT]). Other screening methods
include CT colonography (CTC), colon capsule endoscopy
(CCE) and DNA tests [3]. In a randomised, controlled trial
conducted by our group, subjects randomised to FIT were
more likely to participate in screening than those rando-
mised to colonoscopy. Moreover, on the baseline screen-
ing exam, a similar number of patients with CRC were
detected in each study arm, but more adenomas were
identified in the colonoscopy group [4].
In FIT-positive subjects, colonoscopy is the second
step to confirm colorectal neoplastic lesions [5]. How-
ever, colonoscopy shows a variable risk of complications
(i.e. bleeding or perforation), leading to a low participa-
tion rate. Moreover, in up to 10% of individuals, caecal
intubation is not achieved, and an alternative imaging
technique is needed [6]. In this context, CTC and CCE
have been shown to be valid procedures for such a
purpose [7–9]. Indeed, CTC is a radiological technique
widely accepted by patients, with a high sensitivity and
specificity in detecting significant colorectal lesions [10].
Major limitations are the radiation amount which the in-
dividual is exposed to and its ability to detect small and
flat lesions [10]. On the other hand, CCE is a minimally
invasive and safe method of visualising the entire colon
and represents an alternative for CRC screening and
diagnosis [11, 12]. The second-generation capsule has
demonstrated high sensitivity and specificity in the
detection of patients with polyps [5, 11, 13, 14]. CCE
limitations include the intensive laxative preparation
needed and time required to read every study (40–50
min, approximately). Importantly, both strategies have
never been compared in a parallel manner in order to
determine their specific role in the CRC diagnostic
algorithm.
The aim of the present study was to compare CCE
and CTC for the identification of patients with colorectal
neoplasia among participants in a population-based,
organised CRC screening programme who had a FIT-
positive result. This study design allows us to evaluate
an enriched population with high prevalence of colorec-
tal neoplasms [5].
Methods
Study design and population
The VICOCA study is a prospective, single-centre,
randomised trial (NCT02081742) conducted in a tertiary
referral hospital in Barcelona. Enrolment began in March
2014 and ended in May 2016. The study was approved by
the institutional ethics committee. All authors had access
to the study data, reviewed and approved the final
manuscript.
The primary outcome was to compare performance
characteristics (i.e. sensitivity, specificity, positive and
negative predictive values and overall accuracy) of CCE
and CTC in detecting patients with colorectal neoplastic
lesions, using colonoscopy as an enhanced gold standard
(segmental unblinding has been used to increase the ac-
curacy of our evaluation [15]) in a FIT-positive screening
population.
The secondary outcomes were (1) to compare ad-
vanced colorectal neoplasm detection rate of CCE and
CTC if a threshold of ≥ 6 mm in size was used to indi-
cate the work-up colonoscopy; (2) to determine the
false-positive and false-negative rates of CCE and CTC
in detecting significant lesions (i.e. ≥ 6 mm in size at
colonoscopy), and to identify predictive factors for false-
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negative results of either CCE or CTC; and (3) to deter-
mine the incidence of adverse events associated with each
screening strategy.
Individuals with a positive FIT result (≥ 20 μg of
haemoglobin/g of faeces) from the population-based,
organised CRC screening programme of Barcelona,
which targets men and women aged 50 to 69, were
eligible for the study. Subjects with symptoms, personal
history of inflammatory bowel disease, colorectal aden-
omas, CRC, or total/partial colectomy, or family history
of colorectal polyposis or other inherited disorders, were
excluded from the screening programme, and therefore,
they were not eligible for the study. Individuals with any
contraindication for CCE and CTC, such as suspected
intestinal stricture or allergy to study drugs, were ex-
cluded from the study.
All eligible individuals without exclusion criteria
signed an informed consent form at the local screening
office and were randomly allocated to CCE or CTC
through a computer-generated list. Sealed opaque enve-
lopes were created by an external nurse not participating
in the study. Colonoscopy was performed 1–2 weeks
after these procedures and used as the gold standard in
both groups. For correct anatomical correlation of find-
ings of each examination, the colon was divided into six
segments: caecum, ascending colon, transverse colon,
descending colon, sigmoid and rectum.
After colonoscopy, any relevant therapeutic procedures
were undertaken if necessary. Subsequently, patients were
followed at an outpatient clinic to detect any potential
adverse event appearing within 30 days of colonoscopy.
Colon capsule endoscopy
Colon capsule retrieves images of the entire colon in a
minimally invasive manner without the need for insuffla-
tion. It is a 11 × 33 mm long device swallowed by the
patient that traverses the entire digestive tube with the
help of normal peristaltic movements [16].
The second-generation CCE used in this study (PillCam®
COLON2 Capsule Endoscopy; Medtronic, Minneapolis,
MN) has two cameras, one at each end, with a 172-degree
angle in each camera. The Rapid software, versions 7 and
8, includes a ‘polyp size estimation software’ that calcu-
lates the polyp length by moving the cursor from one end
of the polyp to the other [11, 12].
The CCE preparation included a low-volume laxative
solution (Moviprep®: PEG-3350, sodium sulphate, so-
dium chloride, potassium chloride, sodium ascorbate
and ascorbic acid for oral solution; Norgine B. V, UK)
combined with Gastrografin® (diatrizoate meglumine and
diatrizoate sodium solution USP; Berlimed SA, Madrid,
Spain) [15] (Table S1). The cleansing level was evalu-
ated based on a previously validated scale [17, 18] and
classified as poor (large amount of faecal residue), fair
(enough residue to preclude a completely reliable
examination), good (small amount of residue, not
enough to interfere with examination) and excellent
(no more than small bits of adherent faeces) for each
colonic segment. Examinations scored as ‘poor’ or ‘fair’
in any segment were considered ‘inadequate’, whereas
those scored as ‘good’ or ‘excellent’ in all segments
were considered ‘adequate’.
Lesions identified by CCE were classified according to
their morphology as sessile, pedunculated or flat. All
videos and images were reviewed by two expert CCE
readers (BGS and IKA) before colonoscopy.
CT colonography
CT colonography obtains 2D and 3D images of the
colon through CT. It works by insufflating air or CO2
into the colon through a flexible rectal cannula to
achieve appropriate distension. In this study, a 64-
Chanel CT scanner (Sensation; Siemens, Germany) was
used. No intravenous contrast agent was administered
during the procedure to any patient, except to perform
the staging when a CRC was detected.
In preparation for the CTC, no laxative was used
[19–21]. Individuals were required to consume a non-
fibre diet and 7.5 ml of Gastrografin® diluted in water
2 days before the CTC (five doses per day at breakfast,
mid-morning, lunch, afternoon and dinner). Taking
200 ml of Nutrison standard® (Nutricia, Ireland) as a
diet supplement was deemed optional. Drinking a large
quantity of water was also recommended during the
preparation.
Colonic distension was carried out using CO2 from
an automated insufflator (PROTOCO2L® colon insuffla-
tor, E-Z-EM, Monroe Township, NJ). A scout view of
the abdomen was obtained once signs of a distended
colon were evident, and CT was then performed in
prone position. This procedure was repeated in supine
position. The analysis of images was achieved by 2D
primary reading, using 3D as problem solving. If lesions
suggesting a malignant nature were detected in the first
acquisition (prone position), intravenous contrast was
administered for the second one (supine) and an appro-
priate extension study was carried out. The maximum
duration of the procedure was 20 min and was done
with low radiation dose and non-cathartic preparation.
The quality of examination was classified as ‘adequate’,
partial or inadequate based on three parameters: amount
of residue in the colon lumen, distension of the colon
and faecal tagging.
According to their morphology, lesions were classified
as sessile, pedunculated and flat. They were measured in
the cross section where the largest diameter was found.
An expert radiologist (MP), with over 10 years of
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experience in this technique, examined all CTC readings
before colonoscopy.
Colonoscopy
All colonoscopies were performed under deep sedation
overseen by an anaesthesiologist and after proper bowel
preparation. Colonoscopy was carried out by experi-
enced endoscopists with a global adenoma detection rate
of 54.9% in FIT-based screening [4], who were blinded
to the results of prior examinations (i.e. CCE and CTC).
The cleansing level was evaluated according to the
Boston Bowel Preparation Scale [17]. Examinations with
a total score < 6 points, or < 2 points in any segment,
were considered inadequate, and therefore, they were
repeated. The Paris classification [18, 22] was used to
describe the identified lesions.
All lesions detected during colonoscopy were removed
and/or biopsied following the usual protocol to obtain a
histological description of each lesion. Advanced colorec-
tal neoplasm was defined as invasive cancer, advanced ad-
enoma or advanced serrated lesions. Adenomas ≥ 10mm
in size, with villous architecture, high-grade dysplasia or
intramucosal carcinoma were classified as advanced aden-
omas. Serrated lesions ≥ 10mm in size or with dysplasia
were considered advanced serrated lesions. Invasive can-
cer was considered when malignant cells were observed
beyond the muscularis mucosa. Tumour staging was
performed according to the AJCC classification. Patients
were classified according to the most advanced lesion [4].
Lesion matching
During colonoscopy, the endoscopist who read the CCE
or the radiologist who carried out the CTC remained at
the examination room for a segmental unblinded revi-
sion. Indeed, if a lesion measuring ≥ 6 mm in diameter
was seen on CCE or CTC but not in the initial colonos-
copy, the endoscopist re-examined the corresponding
colonic segment.
A lesion-matching algorithm was used to address
inherent uncertainties in the comparison of localisations
and sizes. For a given lesion to be considered a true
positive match between CCE or CTC and colonoscopy,
it has to be assessed as appearing within the same co-
lonic segment or in adjacent segments, and the two re-
corded diameters had to be the same, with a 50% margin
of error [23]. In case of discrepancies, an independent
panel of experts (constituted by one endoscopist, one
radiologist and one capsule reader) made the final deci-
sion based on the photographs and CT images of the
identified lesions. Lesions observed by CCE or CTC, and
not identified later by colonoscopy, were considered as a
false-positive result of the first examination. When this
circumstance occurred, colonoscopy was repeated only if
there was a high degree of suspicion of a missing lesion.
Sample size and power calculation
As mentioned before, this study was aimed at comparing
the performance of CCE and CTC for the identification
of patients with colorectal neoplasia among FIT-positive
participants in a population-based, organised CRC
screening programme, which constitute an enriched
population for colorectal neoplasms (i.e. prevalence of
neoplastic lesions over 60% [4, 24]). In such a context, it
was assumed that CCE would detect a similar number of
lesions as the gold standard, whereas a difference ≥ 15%
between CCE and CTC would be considered clinically
significant. Accordingly, sample size was estimated in
173 individuals per group, with a 5% level of significance
and a statistical power of 80%.
Statistical analysis
Study outcomes were assessed by intention-to-screen
(main analysis) and per-protocol (secondary analysis).
While the former analysis included all individuals who
complete the study (i.e. colonoscopy), the latter was
limited to those completing the study in whom CCE and
CTC was fully evaluable.
Performance characteristics of CCE and CTC in de-
tecting patients with colorectal neoplastic lesions, using
colonoscopy as the gold standard, include sensitivity,
specificity, positive and negative predictive values and
overall accuracy. These figures were calculated consider-
ing both patients with any neoplastic lesion detected at
colonoscopy and only those in whom neoplastic lesions
≥ 6 mm or ≥ 10mm in size measured at colonoscopy
were found, with a 95% confidence interval.
On the other hand, the detection rate was calculated
as the number of individuals in whom colorectal lesions
(i.e. cancer, advanced neoplasm or any neoplastic lesion)
were detected in each study arm with respect to the
number of patients in whom the corresponding lesions
were identified at colonoscopy, if a threshold of ≥ 6mm
in size of lesions detected by either CTC or CCE was
used to indicate the work-up colonoscopy.
The chi-squared test was used to compare categorical
variables and Student’s t test for continuous variables.
Independent predictors for false-negative results of
either CCE or CTC were ascertained in a multivariable
logistic regression analysis including individual’s demo-
graphics (gender and age), polyp characteristics (size,
location and histology) and imaging quality parameters
of both techniques.
A p value < 0.05 was considered statistically significant
in all analyses. The IBM SPSS package (version 21.0)
was used for the statistical analysis.
Results
Six-hundred and sixty-two FIT-positive participants in the
CRC Screening Programme of Barcelona were eligible for
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this study. Three-hundred and forty-nine individuals
agreed to participate, signed the informed consent form
and were included in the study. The flow chart of the study
is depicted in Fig. 1. As it is shown, 313 out of 662 subjects
(47.2%) declined to participate in the study, there being no
differences with those who actually did in terms of demo-
graphic characteristics and detected lesions (Table S2). The
main reason for non-acceptance to participate was the lack
of time to perform the study tests.
Twenty-six individuals of the CCE group and 33 indi-
viduals of the CTC group cancelled the examination, there
being no difference in acceptance between both groups
[CCE, 147 (84.9%) individuals; CTC, 143 (81.3%) individ-
uals; p = 0.35]. In addition, two individuals in each group
did not complete colonoscopy, and therefore, they were
not considered in all remaining analyses. Therefore, 286
individuals were included in the intention-to-screen
analysis (50% female; mean age, 60.1 ± 5.7 years old): 145
in the CCE group and 141 in the CTC group. Finally, 27
individuals in whom CCE could not be adequately
evaluated and 2 subjects with inadequate quality CTC
Fig. 1 Flow chart of the study
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examination were not included in the per-protocol
analysis (Fig. 1).
Table 1 shows the demographic characteristics and
colonoscopy findings of individuals included in the
intention-to-screen analysis. All colonoscopies were
complete (i.e. examination reached the caecum). Sixteen
(5.6%) colonoscopies were repeated due to inadequate
preparation and the combination of both examinations
was used as the gold standard for the study. Overall,
98.9% of colonoscopies had an acceptable bowel prepar-
ation. The ascending colon cleansing level was adequate
in 99.6% of patients, transverse colon in 99.6% and
descending-sigmoid and rectum in 99.3% of patients.
Lesions were detected in 206 out of 286 (72.0%)
individuals: 135 (47.2%) had lesions ≥ 6 mm, 77
(26.9%) had lesions ≥ 10 mm and 12 (4.1%) had CRC.
As it is shown in Table 1, there were no significant
differences between study groups regarding lesions
detected at colonoscopy.
Diagnostic performance
In the CCE group, adequate preparation (excellent or
good prep) was achieved in 118 out of 145 individuals
(81.7%). In the intention-to-screen analysis, sensitivity,
specificity and positive and negative predictive values of
CCE examination for the detection of patients with any
neoplastic lesion were 98.1%, 76.6%, 93.7% and 92.0%,
respectively (Table 2). Two patients (1.4%) presented
Table 1 Demographic characteristics and colonoscopy findings of individuals included in the intention-to-screen analysis
CCE group (n = 145) CTC group (n = 141) p value
Demographics
Age (years old)1 60.1 (5.8) 60.0 (5.9) 0.79
Gender 0.05
Male 83 (57.2%) 64 (45.4%)
Female 62 (42.8%) 77 (54.6%)
Findings at colonoscopy
Repeat colonoscopy 0.74
No 138 (95.2%) 131 (93.6%)
Yes 7 (4.8%) 9 (6.4%)
Number of lesions1 2.7 (3.7) 2.1 (3.4) 0.15
Any lesion2 (regardless of size) 0.06
No 33 (22.8%) 47 (33.3%)
Yes 112 (77.2%) 94 (66.7%)
Any lesion ≥ 6 mm 0.06
No 68 (46.9%) 83 (58.9%)
Yes 77 (53.1%) 58 (41.1%)
Any lesion ≥ 10 mm 0.35
No 108 (74.5%) 101 (71.6%)
Yes 37 (25.5%) 40 (28.4%)
Invasive cancer 0.35
No 141 (97.2%) 133 (94.3%)
Yes 4 (2.8%) 8 (5.7%)
Advanced neoplasm3 0.44
No 102 (70.3%) 97 (68.7%)
Yes 43 (29.7%) 44 (31.2%)
Serrated lesions 0.68
No 108 (74.5%) 109 (77.3%)
Yes 37 (25.5%) 32 (22.7)
CCE colon capsule endoscopy, CTC CT colonography
1Continuous variables are expressed as mean (standard deviation)
2Any neoplastic lesion includes cancer, advanced and non-advanced adenomas, and advanced and non-advanced serrated lesions
3Advanced neoplasm includes invasive cancer, advanced adenomas and advanced serrated lesions
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lesions at colonoscopy not detected by CCE (false-nega-
tive results): one patient had two 4-mm sessile polyps in
the sigmoid and one 8-mm pedunculated polyp in the
rectum, whereas the second patient had two 2-mm and
3-mm sessile polyps close to the appendicular orifice. In
the first patient, CCE examination was incomplete due
to capsule deactivated at the transverse colon because
the battery ran out. On the other hand, colonoscopy did
not identify any lesion in 7 patients in whom CCE re-
ported 8 lesions, 6 of them ≥ 6mm in size (false-positive
results).
The quality of CTC was considered adequate in 122 out
of 141 individuals (86.6%) based on colon distension,
faecal labelling and absence of faecal residues. In the
intention-to-screen analysis, sensitivity of CTC examin-
ation for the detection of patients with any neoplastic
lesion was 64.9%, with specificity and positive and negative
predictive values of 95.7%, 96.8% and 57.7%, respectively
(Table 2). Thirty-three patients (23.4%) presented lesions
at colonoscopy not detected by CTC (false-negative re-
sults), 11 out of them (7.8%) with lesions ≥ 6mm (three of
them larger than 10mm, 2 sessile polyps and 1 flat polyp).
On the other hand, 2 patients undergoing CTC had one
polyp (5-mm sessile polyp in descending colon and 8-mm
sessile polyp in sigmoid, respectively) that was overlooked
at colonoscopy (false-positive results).
In terms of detecting patients with significant lesions
(i.e. ≥ 6 mm in size at colonoscopy), the sensitivity of
CCE and CTC was 96.1% and 79.3%, respectively (p =
0.0003), whereas the corresponding figures for specificity
were 88.2% and 96.3% (p = 0.03), respectively (Table 2).
The results of the per-protocol analysis are shown
in Table S3. Indeed, after excluding those individuals
in whom either CCE (27 subjects) or CTC (2 sub-
jects) was not fully evaluable (Fig. 1), values of 100%
and 80% for sensitivity of CCE and CTC, respectively,
were observed in detecting patients with significant
lesions (p < 0.00001).
Neoplasm detection rate
Using a threshold of ≥ 6mm in size of lesions detected by
either CCE or CTC, we observed that the detection rate
for advanced colorectal neoplasm in the CCE group was
higher than that in the CTC group, but this difference did
not achieve statistical significance (100% (43 out of 43
Table 2 Diagnostic performance (all figures are expressed as percentages) of colon capsule endoscopy and CT colonography,
according to the intention-to-screen analysis
CCE 95% CI CTC 95% CI Diff. 95% CI
Any neoplastic lesion1
(regardless of size), no. (%)
112 (77.2)2 94 (66.7)2
Sensitivity 98.1 [94.1; 99.4] 64.8 [56.7; 72.2] 33.2 [22.8; 43.0]
Specificity 76.6 [68.8; 82.9] 95.7 [91.0; 98.0] − 19.1 [− 35.6; − 2.4]
PPV 93.6 [88.2; 96.7] 96.8 [92.4; 98.7] − 3.1 [− 9.5; 3.9]
NPV 92.0 [86.2; 95.4] 57.6 [49.4; 65.5] 34.3 [16.9; 48.7]
Accuracy 93.3 [87.9; 96.4] 75.1 [67.4; 81.5] 18.2 [9.7; 26.4]
Any neoplastic lesion1
≥ 6 mm, no. (%)3
77 (53.1)2 58 (41.1)2
Sensitivity 96.1 [91.1; 100] 79.3 [68.6; 88.8] 16.7 [5.2; 28.2]
Specificity 88.2 [79.6; 95.3] 96.3 [91.1; 100] − 8.1 [− 17.1; 0.1]
PPV 90.2 [83.5; 96.1] 93.8 [85.7; 100] − 3.6 [− 12.9; 6.5]
NPV 95.2 [89.2; 100] 86.9 [80.0; 93.2] 8.2 [0.9; 16.9]
Accuracy 92.4 [87.5; 96.5] 89.3 [83.6; 93.6] 3 [− 3.7; 9.8]
Any neoplastic lesion1
≥ 10 mm, no. (%)3
37 (25.5)2 40 (28.4)2
Sensitivity 97.3 [91.1; 100] 90.0 [83.9; 93.9] 7.3 [− 4.5; 18.6]
Specificity 95.3 [90.7; 99.0] 99.0 [95.6; 100] − 3.6 [− 8.3; 1.2]
PPV 87.8 [76.7; 97.3] 97.3 [93.1; 100] − 9.5 [− 21.2; 2.9]
NPV 99.0 [96.8; 100] 96.1 [91.5; 98.2] 2.8 [− 1.6; 7.4]
Accuracy 95.5 [92.4; 99.3] 96.4 [91.9; 98.4] − 0.8 [− 5.2; 4.0]
CCE colon capsule endoscopy, CTC CT colonography, 95% CI 95% confidence interval, PPV positive predictive value, NPV negative predictive value, Diff. difference
1Any neoplastic lesion includes cancer, advanced and non-advanced adenomas, and advanced and non-advanced serrated lesions
2Prevalence of patients with such lesions at colonoscopy
3Lesion size was estimated at colonoscopy
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patients) and 93.1% (41 out of 44 patients), respectively;
RR = 1.07; p = 0.08) (Table 3). Both CCE and CTC identi-
fied all patients with cancer, while CCE detected more
patients with any neoplastic lesion than CTC ((74 out of
75 patients) 98.6% and (47 out of 58 patients) 81.0%,
respectively; RR = 1.22; p = 0.002) (Table 3).
Upon excluding individuals in whom either CCE or
CTC was not fully evaluable (per-protocol analysis), re-
sults did not vary meaningfully (Table S4).
Analysis at lesion level
For the analysis at lesion level, three patients were not
evaluable due to the large number of lesions found at
colonoscopy (Fig. 1), which made it difficult to deter-
mine a precise correlation with CCE and CTC results.
As it is shown in Table 4, a higher number of lesions
were detected by CCE compared to CTC 83.2% (298 out
of 358 lesions) and 42.8% (119 out of 278 lesions),
respectively (p < 0.001). This difference is mainly due to
a higher capability of CCE for detecting small lesions
and lesions with sessile or flat morphology, in compari-
son with CTC (Table 4).
With respect to histology, there were no differences
between both techniques in the detection of cancer or
adenomas with high-grade dysplasia, but CCE was able
to detect a higher number of adenomas with low-grade
dysplasia and serrated lesions than CTC (Table 4).
Predictors for false-negative results
Independent predictive factors for a false-negative result
in CCE examination were lesion size < 6mm (p < 0.001)
and inadequate colonic preparation (p = 0.05). With
respect to CTC, lesion size < 10mm (p < 0.05), caecum or
rectum location (p < 0.05) and serrated histology (p < 0.05)
were independent predictors for a false-negative result.
Adverse events
No serious adverse event was reported in any of the
study groups. In the CCE group, a unique mild adverse
event was observed in a diabetic patient who presented
with vasovagal syndrome after consuming the first prep
booster and recovered spontaneously.
Discussion
This study design allows us to evaluate an enriched popu-
lation with high prevalence of colorectal neoplasms [5],
thus favouring the comparison between CTC and CCE.
Results of this randomised trial demonstrate that CCE was
more sensitive than CTC in the identification of patients
with significant neoplastic lesions (i.e. ≥ 6mm in size at
colonoscopy) (96.1% vs. 79.3%, respectively), which was
translated to a higher neoplasm detection rate (98.6% vs.
81.0%, respectively; RR = 1.22; 95% CI, 1.07–1.38). None-
theless, both techniques identified all patients with CRC
and there was no significant difference in the identification
Table 3 Detection rate (the detection rate was calculated as
the number of individuals in whom colorectal lesions (i.e.
cancer, advanced neoplasm or any neoplastic lesion) were
detected in each study arm with respect to the number of
patients in whom the corresponding lesions were identified at
colonoscopy, if a threshold of ≥ 6 mm in size of lesions
detected by either CTC or CCE was used to indicate the work-
up colonoscopy) of colon capsule endoscopy and CT
colonography, according to the intention-to-screen analysis
Colorectal lesion1 CCE CTC RR 95% CI p value
Cancer 4 (100%) 8 (100%) 1 1.00–1.00 –
Advanced neoplasm2 43 (100%) 41 (93.1%) 1.07 0.99–1.16 0.08
Any neoplastic lesion3 74 (98.6%) 47 (81.0%) 1.22 1.07–1.38 0.002
CCE colon capsule endoscopy, CTC CT colonography, RR relative risk, 95% CI
95% confidence interval
1Patients were classified according to the most advanced lesion
2Advanced neoplasm includes invasive cancer, advanced adenomas and
advanced serrated lesions
3Any neoplastic lesion includes cancer, advanced and non-advanced
adenomas, and advanced and non-advanced serrated lesions
Table 4 Sensitivity (all figures are expressed as percentages (95% confidence interval)) of colon capsule endoscopy and CT
colonography for the detection of lesions, according to size, morphology and histology
CCE [95% CI] CTC [95% CI] p value
Any neoplastic lesion1 (regardless of size) 83.2 [78.9–86.9] 42.8 [37.1–48.7] < 0.001
Any neoplastic lesion1 ≥ 6 mm 91.9 [85.6–95.8] 74.8 [66.2–82.2] 0.001
Any neoplastic lesion1 ≥10 mm 100 [92.9–100] 88 [76.4–94.6] 0.028
Pedunculated lesions 91.1 [79.4–96.9] 80 [62–90.9] 0.185
Sessile lesions 87.3 [81.8–91.5] 44.2 [36.8–51.7] < 0.001
Flat lesions 72.6 [63.3–80.3] 20.8 [12.7–31.7] < 0.001
Cancer 100 [49.9–100] 100 [64.1–100] –
HGD adenomas 100 [74.4–100] 100 [59.4–100] –
LGD adenomas 87.1 [81.9–91.1] 46.4 [38.9–54.1] < 0.001
Serrated lesions 73.6 [61.9–83] 32.9 [22.5–44.9] < 0.001
CCE colon capsule endoscopy, CTC CT colonography, HGD high-grade dysplasia, LGD low-grade dysplasia
1Any neoplastic lesion includes cancer, advanced and non-advanced adenomas, and advanced and non-advanced serrated lesions
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of patients with advanced colorectal neoplasms (100% vs.
93.1%, respectively; RR = 1.07; 95% CI, 0.99–1.16) than
CTC, the latter without reaching statistical significance.
On the contrary, CTC was more specific than CCE (96.3%
vs. 88.2%, respectively) in identifying significant neoplastic
lesions. Interestingly, these results were observed in both
the per-protocol assessment (which was limited to those
individuals in whom CCE and CTC were fully evaluable)
and the intention-to-screen analysis. In that sense, it is
important to mention that CCE could not be evaluated in
18.3% of patients due to incomplete studies. Finally, there
were no significant differences in terms of patients’
acceptance and adverse events between both strategies.
There are numerous publications regarding the use of
CTC for CRC screening that back up the usefulness of
this technique, with sensitivity comparable to conven-
tional colonoscopy. In a seminal article, Pickhardt et al.
demonstrated a sensitivity of 94% for lesions ≥ 10mm
and 89% for those ≥ 6mm [25]. More recent studies
confirmed sensitivity figures ranging from 78 to 90% for
the detection of these lesions [20, 26, 27]. With respect
to CCE, a recent systematic review including over 2000
individuals demonstrate sensitivity values of 87% for
lesions ≥ 10 mm and 86% for those ≥ 10mm, with a spe-
cificity of 95% [28]. Recently, a prospective study evalu-
ating CCE in CRC screening showed a sensitivity of 88%
for the detection of subjects with significant lesions, with
a specificity of 82% [23]. All these figures are very similar
to the ones obtained in the present study, thus confirm-
ing the reproducibility of our results.
Two studies have previously compared CCE and CTC
[29, 30]. Rondonotti et al., including a small number of
individuals and performing unblinded colonoscopy,
showed a similar diagnostic yield for both techniques
[29]. More recently, a second study that focused on
compliance was not able to achieve reliable conclusions
on polyp detection rate because of the lack of a gold
standard in the vast majority of individuals [30].
CCE and CTC represent a two-step approach to CRC
diagnosis, in which the first examination selects those
individuals who should undergo colonoscopy. In that
sense, an adequate balance between sensitivity and speci-
ficity of the first examination is critical to minimise the
risk of missing lesions and to avoid unnecessarily colon-
oscopies, respectively. In the present study, both CCE
and CTC have shown to be safe and highly effective
strategies to detect CRC and advanced adenomas, and
therefore, both constitute adequate strategies for CRC
diagnosis. Issues referred to medical and technical costs
or patient’s preference with respect to these two alterna-
tives should be also ascertained. However, besides
logistics or local restrictions favouring the selection of
one test over the other, CCE may benefit from a higher
sensitivity for detecting any neoplastic lesion with
respect to CTC.
Interestingly, our study was the first evaluation com-
paring the efficacy of CCE and CTC for the identifica-
tion of serrated lesions (Table 4), which represent an
alternative pathway to CRC development. Indeed, these
lesions constitute a new challenge to detection at both
endoscopy and CTC because of their flat morphology. In
the present trial, CCE was superior to CTC in terms of
sensitivity for detecting serrated lesions (73.6% vs. 32.9%,
respectively; p < 0.001), whereas serrated histology was
one of the predictors of false-negative results of CTC.
These results were reinforced by the fact that CCE
detected more sessile and flat lesions than CTC
(Table 4), in concordance with the most common pres-
entation of serrated lesions.
No serious adverse event was reported in our trial, in
concordance with the results of previous studies [12, 14].
This fact supports that both techniques are safe and,
therefore, can be used in a FIT-positive screening setting.
The strength of this study relies on several facts. First,
it is the first prospective evaluation of both CCE and
CTC performed in a parallel manner and using blinded
colonoscopy as the gold standard, which allows
determining their specific role in the CRC diagnostic
algorithm. Second, the main analysis of results was done
by intention-to-screen, thus avoiding the bias of limiting
the analysis to those individuals in whom tested examina-
tions were fully evaluable. Third, this study compared
CCE and CTC among FIT-positive screenees, an enriched
population selected because of its high prevalence of colo-
rectal neoplasms. This circumstance, along with the large
sample size, allows an accurate comparison overall, strati-
fied according to colonoscopy findings, and at polyp level.
We are aware, however, of some limitations of the
study. First, the use of the above-mentioned enriched
population makes it difficult to extrapolate these results
to other screening populations. Indeed, the setting of
FIT-positive screening population is different in terms of
expected yield with respect to one in which CCE or
CTC would have been used as the first screening test in
naïve individuals. However, the fact that subjects in-
cluded in the study were selected among participants in
a population-based, organised screening programme
guarantees an appropriate comparison of the perform-
ance of each technique, which is the primary outcome of
the study. Second, patients’ acceptance can be overesti-
mated since it has been obtained in a highly motivated
population. Nevertheless, this circumstance does not
preclude an adequate comparison of subject’s prefer-
ences with respect to each option. Third, a higher than
expected drop-out rate in both screening strategies may
have contributed to the lack of a significant difference
when comparing them in terms of advanced neoplasm
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detection rate. This fact, along with difficulties in the
recruitment (47.2% of patients declined to participate
due to lack of time to perform both diagnostic tests),
resulted in an evaluable study population lower than
expected. Fourth, since bowel preparation is a critical
issue for both CCE and CTC, it cannot be excluded that
results might differ depending on the protocol used. Fi-
nally, because of the low number of patients with
serrated lesions, it was not possible to analyse perform-
ance characteristics of both imaging techniques for each
histological subtype (i.e. sessile serrated adenomas/
polyps, traditional serrated adenomas and hyperplastic
polyps).
Conclusions
In summary, according to the results obtained in our
enriched cohort of FIT-positive individuals, CCE and
CTC seem to be equivalent in terms of advanced neo-
plasm detection rate. However, CCE may benefit from a
higher sensitivity for detecting small, flat, sessile and
serrated lesions. The impact of this advantage in terms
of overall effectiveness deserves further investigations.
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